The US-centred and Dublin-headquartered pharmaceutical group Mallinckrodt is expected to enter examinership for the second time in less than two years after a previous restructuring failed to give it enough runway. A small factory at the IDA’s College Park in Blanchardstown is not only the pharma giant’s registered head office, but also the owner of the multi-billion-dollar intellectual property behind its highest-value drugs, such as the anti-inflammatory Acthar and a suite of immunotherapy, lung and kidney treatments.  This Irish presence already triggered the largest examinership in the history of the State in January 2022, when costly litigation on multiple fronts…

Want to continue reading?

Join today with an Annual membership and get full access to The Currency for just €200 (68c per day) or try monthly membership for just €5 for your first month.

Subscribe

Cancel at any time.

Are you already a member? .